Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1996 Jun;88(2):230–237. doi: 10.1111/j.1365-2567.1996.tb00009.x

Sensitization of T-cell receptor-alpha beta+ T cells recovered from long-term T-cell receptor downmodulation.

K Omoto 1, Y Y Kong 1, K Nomoto 1, M Umesue 1, Y Murakami 1, M Eto 1, K Nomoto 1
PMCID: PMC1456440  PMID: 8690455

Abstract

Although the survival of fully allogeneic skin grafts was prominently prolonged by adult thymectomy in anti-T-cell receptor-alpha beta monoclonal antibody (TCR-alpha beta mAb)-treated mice compared with that of non-adult thymectomized (ATX) mice, the skin allografts were eventually rejected. In the anti-TCR-alpha beta mAb-treated ATX mice, as shown in the present study, most of TCR-alpha beta+ cells were promptly activated on day 2 and then rapidly disappeared by day 7, but some TCR-alpha beta- Thy-1+ cells remained at that time. These TCR-alpha beta- Thy-1+ cells which have downmodulated their TCR-alpha beta expression may be refractory to depletion events by the mAb treatment. Although these downmodulated T cells re-expressed their TCR-alpha beta on day 50, they could not respond to stimuli via TCR such as TCR cross-linking or alloantigens. However, they recovered the reactivity to donor antigens on day 85. These results indicate that the downmodulated T cells by anti-TCR-alpha beta mAb treatment are long-lived and re-express their TCR-alpha beta at a late stage to be sensitized to donor antigen, which suggests that additional regimens may be required to get permanent, or very long-term, graft acceptance.

Full text

PDF
230

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babbitt B. P., Allen P. M., Matsueda G., Haber E., Unanue E. R. Binding of immunogenic peptides to Ia histocompatibility molecules. 1985 Sep 26-Oct 2Nature. 317(6035):359–361. doi: 10.1038/317359a0. [DOI] [PubMed] [Google Scholar]
  2. Buus S., Sette A., Colon S. M., Jenis D. M., Grey H. M. Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell. 1986 Dec 26;47(6):1071–1077. doi: 10.1016/0092-8674(86)90822-6. [DOI] [PubMed] [Google Scholar]
  3. Chace J. H., Cowdery J. S., Field E. H. Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol. 1994 Jan 15;152(2):405–412. [PubMed] [Google Scholar]
  4. Eto M., Yoshikai Y., Nishimura Y., Hiromatsu K., Maeda T., Nomoto K., Kong Y. Y., Kubo R. T., Kumazawa J., Nomoto K. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection. Immunology. 1994 Feb;81(2):198–204. [PMC free article] [PubMed] [Google Scholar]
  5. Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc. 1987 Apr;19(2 Suppl 1):1–6. [PubMed] [Google Scholar]
  6. Hirsch R., Eckhaus M., Auchincloss H., Jr, Sachs D. H., Bluestone J. A. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol. 1988 Jun 1;140(11):3766–3772. [PubMed] [Google Scholar]
  7. Hämmerling G. J., Schönrich G., Ferber I., Arnold B. Peripheral tolerance as a multi-step mechanism. Immunol Rev. 1993 Jun;133:93–104. doi: 10.1111/j.1600-065x.1993.tb01511.x. [DOI] [PubMed] [Google Scholar]
  8. Kubo R. T., Born W., Kappler J. W., Marrack P., Pigeon M. Characterization of a monoclonal antibody which detects all murine alpha beta T cell receptors. J Immunol. 1989 Apr 15;142(8):2736–2742. [PubMed] [Google Scholar]
  9. Mayumi H., Nomoto K., Good R. A. A surgical technique for experimental free skin grafting in mice. Jpn J Surg. 1988 Sep;18(5):548–557. doi: 10.1007/BF02471489. [DOI] [PubMed] [Google Scholar]
  10. Murakami Y., Kong Y. Y., Nishimura Y., Nomoto K., Umesue M., Omoto K., Maeda T., Nomoto K. Prevention of anti-T-cell receptor alpha beta monoclonal antibody-induced side-effects by treatment with cyclosporin A without interference of monoclonal antibody-induced immunosuppression in mice. Immunology. 1995 Oct;86(2):238–243. [PMC free article] [PubMed] [Google Scholar]
  11. Schlitt H. J., Schwinzer R., Kurrle R., Wonigeit K. Evidence for a cyclosporine-resistant pathway of T cell activation triggered via the CD3/T cell receptor complex. Transplant Proc. 1988 Apr;20(2 Suppl 2):103–109. [PubMed] [Google Scholar]
  12. Thistlethwaite J. R., Jr, Cosimi A. B., Delmonico F. L., Rubin R. H., Talkoff-Rubin N., Nelson P. W., Fang L., Russell P. S. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation. 1984 Dec;38(6):695–701. doi: 10.1097/00007890-198412000-00029. [DOI] [PubMed] [Google Scholar]
  13. Tsuchida M., Hirahara H., Matsumoto Y., Abo T., Eguchi S. Induction of specific unresponsiveness to cardiac allografts by short-term administration of anti-T cell receptor alpha beta antibody. Transplantation. 1994 Jan;57(2):256–262. doi: 10.1097/00007890-199401001-00018. [DOI] [PubMed] [Google Scholar]
  14. Vigeral P., Chkoff N., Chatenoud L., Campos H., Lacombe M., Droz D., Goldstein G., Bach J. F., Kreis H. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation. 1986 Jun;41(6):730–733. doi: 10.1097/00007890-198606000-00013. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES